×
Clene Total Long Term Liabilities 2018-2025 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Clene total long term liabilities from 2018 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
Clene Total Long Term Liabilities 2018-2025 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Clene total long term liabilities from 2018 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$218.1B
Amgen (AMGN)
$157.3B
Gilead Sciences (GILD)
$135.7B
Vertex Pharmaceuticals (VRTX)
$119.2B
Bristol Myers Squibb (BMY)
$94.5B
CSL (CSLLY)
$78.8B
GSK (GSK)
$77.4B
Regeneron Pharmaceuticals (REGN)
$59.2B
Alnylam Pharmaceuticals (ALNY)
$40.6B
Argenex SE (ARGX)
$34B
BioNTech SE (BNTX)
$26.6B
Royalty Pharma (RPRX)
$20.5B
Insmed (INSM)
$19.5B
Biogen (BIIB)
$18.7B
Illumina (ILMN)
$15.4B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.6B
Incyte (INCY)
$13.2B
Moderna (MRNA)
$12.2B
Exelixis (EXEL)
$12B
BioMarin Pharmaceutical (BMRN)
$10.9B
Ascendis Pharma (ASND)
$10.7B
QIAGEN (QGEN)
$10.5B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$10B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.4B
Bio-Techne Corp (TECH)
$8.1B
Roivant Sciences (ROIV)
$7.7B
Legend Biotech (LEGN)
$7.3B